Navigation Links
Imanis Life Sciences Launches Line of Oncolytic Vaccinia Viruses Encoding Reporter Genes From Genelux Corporation
Date:2/23/2017

ROCHESTER, Minn., Feb. 23, 2017 /PRNewswire/ -- Imanis Life Sciences announced today the launch of a new product line of oncolytic vaccinia viruses for virotherapy research. These viruses are licensed from Genelux Corporation as part of Genelux's proprietary, vaccinia virus-based technology platform for research use.

"We are excited to enter into a partnership with Genelux to offer researchers, for the first time, selected oncolytic vaccinia viruses for use in research," said Dr. Kah Whye Peng, Chief Operating Officer of Imanis. "Genelux Corporation has an extraordinarily strong portfolio of recombinant vaccinia viruses that encode novel reporter genes, and we are delighted to partner with them to offer researchers these important new tools for research."

Oncolytic virotherapy has emerged as a new immunotherapeutic treatment modality that uses replication-competent viruses to target and destroy cancer cells. In 2015, the U.S. Food and Drug Administration approved the first oncolytic virus, T-VEC (Imlygic®), for the treatment of metastatic melanoma.

Researchers rely on well-characterized oncolytic viruses to establish equivalence or superiority in preclinical studies. Imanis' repository of well-characterized recombinant oncolytic viruses includes measles virus, vesicular stomatitis virus, herpes simplex virus, and vaccinia virus to facilitate this research.

"In the new immunotherapy era, the power of oncolytic viruses is gaining momentum, and research utilizing some of our preclinical strains will encourage the development and refinement of cancer immunotherapies," said Thomas Zindrick, Chief Executive Officer of Genelux. "We believe that providing scientists with some of our most in-demand preclinical recombinant vaccinia virus strains will facilitate development of novel oncolytic vaccinia virus-based combination therapies. Imanis' expertise and existing infrastructure will facilitate the use of safe, effective oncolytic virus products in combination therapy research."

Imanis will initially offer two vaccinia viruses engineered to express reporter genes to facilitate tracking in culture dishes and in animals, and will launch several other vaccinia viruses by the end of 2017. One of the vaccinia viruses currently available from Imanis encodes the sodium iodide symporter (NIS). NIS imaging by SPECT or PET provides a high-resolution 3D picture of where the virus is in the animal. The two viruses are:

  • VV(Li)-RucGFP-hNIS-tRFP, which encodes optical imaging reporter genes and the NIS protein
  • VV(Li)-RucGFP-mTyr-GusA, which encodes tyrosinase, the primary enzyme responsible for melanin production, allowing it to be imaged by photoacoustic imaging

About Imanis Life Sciences
Imanis Life Sciences provides biotechnology and pharmaceutical companies products and services in the fields of oncolytic virotherapy and noninvasive reporter gene imaging. Headquartered in Rochester, Minnesota, Imanis offers the world's only commercially available recombinant oncolytic virus repository. Imanis also provides scientists with ready-to-use reporter gene cell lines, reporter lentiviruses, and antibodies, to support research in regenerative medicine, gene therapy, oncology, and virotherapy. Imanis also offers contract research services and support for studies in oncolytic virotherapy and preclinical imaging. For more information please visit www.imanislife.com.

About Genelux Corporation
Headquartered in San Diego, California, Genelux Corporation is a privately-held, clinical-stage biopharmaceutical company dedicated to fundamentally changing the way in which caner is diagnosed and treated. The company has developed a proprietary, vaccinia virus-based technology platform. Such a platform can also be engineered to insert specific genes for delivery of therapeutic and diagnostic proteins. For more information please visit www.genelux.com.

CONTACT:
Rianna Vandergaast
Imanis Life Sciences
507-218-2559
vandergaast.rianna@imanislife.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/imanis-life-sciences-launches-line-of-oncolytic-vaccinia-viruses-encoding-reporter-genes-from-genelux-corporation-300412615.html


'/>"/>
SOURCE Imanis Life Sciences
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. ProMIS Neurosciences issues white paper entitled “Results from recent Alzheimer’s disease trials validate the ProMIS approach”
2. Vortex Biosciences Announces Commercial Launch of Fully Automated System for CTC Isolation
3. Global Consulting and Strategic Solutions Provider, Treximo, LLC, Announces Launch of Life Sciences Division
4. Caprion Biosciences wird Kurzlehrgang und Poster bei Molecular Medicine Tri-Conference in San Francisco präsentieren
5. Teewinot Life Sciences Corporation Announces Breakthrough Commercial Production of the Cannabinoid Varin Series
6. CSO of Vortex Biosciences Dr. Elodie Sollier-Christen Awarded With 2017 SLAS Innovation Award
7. Swift Biosciences Expands Team, Hires Vice President of Marketing
8. Life Sciences Forum Executives Announced
9. Knowledgent Clinical Cloud Built on Amazon Web Services Transforms Clinical Informatics in Life Sciences
10. Exact Sciences to participate in Leerink Partners Global Healthcare Conference
11. ACEA Biosciences Announces Winners of its Travel Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... 2017 , ... Stratevi, a boutique firm that partners with healthcare companies to ... an office in downtown Boston at 745 Atlantic Ave. , “We are seeing ... evidence on the value they provide, not just to patients, but also payers. Having ...
(Date:5/22/2017)... , ... May 22, 2017 , ... ... that it is exhibiting in booth B2 at the Association for Pathology ... 22-25. , In addition to demonstrating its Cancer Diagnostic Cockpit and Consultation ...
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose is ... trial and error process by finding the right antidepressant faster. CNSDose speeds ... doctor-patient relationship through a personalized approach to treatment. , A peer-reviewed ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City Science ... technologies ripe for commercialization, and who are affiliated with the 21 partner academic ... proposals. QED, now in its tenth round, is the first multi-institutional proof-of-concept program ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):